Ding-Wei Ye

List of Publications by Year
in descending order

123 papers	2,084 citations	318942 23 h-index	388640 36 g-index
127 all docs	127 docs citations	127 times ranked	3215 citing authors

#	Article	IF	Citations
1	Prognostic value and immune infiltration of novel signatures in clear cell renal cell carcinoma microenvironment. Aging, 2019, 11, 6999-7020.	1.4	163
2	Prostate cancer in East Asia: evolving trend over the last decade. Asian Journal of Andrology, 2015, 17, 48.	0.8	90
3	Inactivation of the AMPKâ€"GATA3â€"ECHS1 Pathway Induces Fatty Acid Synthesis That Promotes Clear Cell Renal Cell Carcinoma Growth. Cancer Research, 2020, 80, 319-333.	0.4	90
4	Preoperative lymphocyte-monocyte and platelet-lymphocyte ratios as predictors of overall survival in patients with bladder cancer undergoing radical cystectomy. Tumor Biology, 2015, 36, 8537-8543.	0.8	71
5	A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings. European Urology, 2019, 75, 558-561.	0.9	64
6	MicroRNA-302a Suppresses Tumor Cell Proliferation by Inhibiting AKT in Prostate Cancer. PLoS ONE, 2015, 10, e0124410.	1.1	58
7	Metabolic syndrome and renal cell carcinoma. World Journal of Surgical Oncology, 2014, 12, 236.	0.8	46
8	Surgical management of penile carcinoma <i>in situ</i>: results from an international collaborative study and review of the literature. BJU International, 2018, 121, 393-398.	1.3	45
9	Long noncoding RNA expression signatures of bladder cancer revealed by microarray. Oncology Letters, 2014, 7, 1197-1202.	0.8	41
10	Relationship between circumcision and human papillomavirus infection: a systematic review and meta-analysis. Asian Journal of Andrology, 2017, 19, 125.	0.8	39
11	Hexokinase 3 dysfunction promotes tumorigenesis and immune escape by upregulating monocyte/macrophage infiltration into the clear cell renal cell carcinoma microenvironment. International Journal of Biological Sciences, 2021, 17, 2205-2222.	2.6	36
12	Impact of preoperative 5α-reductase inhibitors on perioperative blood loss in patients with benign prostatic hyperplasia: a meta-analysis of randomized controlled trials. BMC Urology, 2015, 15, 47.	0.6	33
13	Evaluation of fine particles in surgical smoke from an urologistâ€™s operating room by time and by distance. International Urology and Nephrology, 2015, 47, 1671-1678.	0.6	33
14	Critical appraisal of sorafenib in the treatment of Chinese patients with renal cell carcinoma. OncoTargets and Therapy, 2014, 7, 925.	1.0	32
15	Extent of pelvic lymph node dissection in penile cancer may impact survival. World Journal of Urology, 2016, 34, 353-359.	1.2	32
16	Management of patients with advanced prostate cancer in the Asia Pacific region: â€˜realâ€™worldâ€™ consideration of results from the Advanced Prostate Cancer Consensus Conference <scp>(APCCC)</scp> 2017. BJU International, 2019, 123, 22-34.	1.3	32
17	Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer. Oncotarget, 2015, 6, 41825-41836.	0.8	29
18	Evaluation of ^{99m}Tc-labeled PSMA-SPECT/CT imaging in prostate cancer patients who have undergone biochemical relapse. Asian Journal of Andrology, 2017, 19, 267.	0.8	29

#	Article	IF	Citations
19	Elevated CD36 expression correlates with increased visceral adipose tissue and predicts poor prognosis in ccRCC patients. Journal of Cancer, 2019, 10, 4522-4531.	1.2	29
20	Screening and Identification of Potential Prognostic Biomarkers in Adrenocortical Carcinoma. Frontiers in Genetics, 2019, 10, 821.	1.1	28
21	Large‐scale transcriptome profiles reveal robust 20‐signatures metabolic prediction models and novel role of G6PC in clear cell renal cell carcinoma. Journal of Cellular and Molecular Medicine, 2020, 24, 9012-9027.	1.6	28
22	Reactive stroma component COL6A1 is upregulated in castration-resistant prostate cancer and promotes tumor growth. Oncotarget, 2015, 6, 14488-14496.	0.8	27
23	Laser ablation as monotherapy for penile squamous cell carcinoma: A multi-center cohort analysis. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 147-152.	0.8	26
24	Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors. BMC Cancer, 2017, 17, 16.	1.1	25
25	Predicting the failure of retrograde ureteral stent insertion for managing malignant ureteral obstruction in outpatients. Oncology Letters, 2016, 11, 879-883.	0.8	24
26	An Integrated Score and Nomogram Combining Clinical and Immunohistochemistry Factors to Predict High ISUP Grade Clear Cell Renal Cell Carcinoma. Frontiers in Oncology, 2018, 8, 634.	1.3	24
27	Pretreatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with metastatic renal cell carcinoma receiving targeted therapy. International Journal of Clinical Oncology, 2016, 21, 373-378.	1.0	23
28	Elevated MRE11 expression associated with progression and poor outcome in prostate cancer. Journal of Cancer, 2019, 10, 4333-4340.	1.2	23
29	Chemokine Receptors CXCR4 and CXCR7 are Associated with Tumor Aggressiveness and Prognosis in Extramammary Paget Disease. Journal of Cancer, 2017, 8, 2471-2477.	1.2	22
30	Modification of American Joint Committee on cancer prognostic groups for renal cell carcinoma. Cancer Medicine, 2018, 7, 5431-5438.	1.3	21
31	Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients. Asian Journal of Andrology, 2017, 19, 178.	0.8	21
32	Prevalence of comprehensive <scp>DNA</scp> damage repair gene germline mutations in Chinese prostate cancer patients. International Journal of Cancer, 2021, 148, 673-681.	2.3	20
33	Prognostic significance of the TREK-1 K2P potassium channels in prostate cancer. Oncotarget, 2015, 6, 18460-18468.	0.8	20
34	Construction of an immune‐related LncRNA signature with prognostic significance for bladder cancer. Journal of Cellular and Molecular Medicine, 2021, 25, 4326-4339.	1.6	19
35	Decreased SPTLC1 expression predicts worse outcomes in ccRCC patients. Journal of Cellular Biochemistry, 2020, 121, 1552-1562.	1.2	18
36	Pathological Features of Localized Prostate Cancer in China: A Contemporary Analysis of Radical Prostatectomy Specimens. PLoS ONE, 2015, 10, e0121076.	1.1	18

#	Article	IF	Citations
37	Extended versus non-extended lymphadenectomy during radical cystectomy for patients with bladder cancer: a meta-analysis of the effect on long-term and short-term outcomes. World Journal of Surgical Oncology, 2019, 17, 225.	0.8	17
38	A Multicenter, Randomized Clinical Trial Comparing the Three-Weekly Docetaxel Regimen plus Prednisone versus Mitoxantone plus Prednisone for Chinese Patients with Metastatic Castration Refractory Prostate Cancer. PLoS ONE, 2015, 10, e0117002.	1.1	17
39	Prognostic value of epithelial-mesenchymal transition markers in clear cell renal cell carcinoma. Aging, 2020, 12, 866-883.	1.4	17
40	The association between metabolic syndrome and advanced prostate cancer in Chinese patients receiving radical prostatectomy. Asian Journal of Andrology, 2015, 17, 839.	0.8	17
41	Identification of seven long noncoding RNAs signature for prediction of biochemical recurrence in prostate cancer. Asian Journal of Andrology, 2019, 21, 618.	0.8	17
42	Phenotypes of circulating tumour cells predict time to castration resistance in metastatic castration‐sensitive prostate cancer. BJU International, 2019, 124, 258-267.	1.3	16
43	Development and external validation of a prostate health index-based nomogram for predicting prostate cancer. Scientific Reports, 2015, 5, 15341.	1.6	15
44	Assessment of survival of patients with metastatic clear cell renal cell carcinoma after radical cytoreductive nephrectomy versus no surgery: a SEER analysis. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2015, 41, 288-295.	0.7	15
45	Glansectomy as Primary Management of Penile Squamous Cell Carcinoma: An International Study Collaboration. Urology, 2017, 109, 140-144.	0.5	15
46	Genetic variations of the ADIPOQgene and risk of prostate cancer in Chinese Han men. Asian Journal of Andrology, 2014, 16, 878.	0.8	15
47	Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study. , 2022, 10, e004427.		15
48	Testicular desmoplastic small round cell tumor: a case report and review of literature. World Journal of Surgical Oncology, 2014, 12, 227.	0.8	14
49	Important Therapeutic Considerations in T1b Penile Cancer: Prognostic Significance and Adherence to Treatment Guidelines. Annals of Surgical Oncology, 2019, 26, 685-691.	0.7	14
50	The Value of 99mTc-PSMA SPECT/CT-Guided Surgery for Identifying and Locating Lymph Node Metastasis in Prostate Cancer Patients. Annals of Surgical Oncology, 2019, 26, 653-659.	0.7	14
51	Camrelizumab plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study. Clinical Cancer Research, 2021, 27, 5838-5846.	3.2	14
52	Clinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective study. Oncotarget, 2015, 6, 36870-36883.	0.8	14
53	Serum lipid profiles: novel biomarkers predicting advanced prostate cancer in patients receiving radical prostatectomy. Asian Journal of Andrology, 2015, 17, 239.	0.8	14
54	Procollagen-lysine, 2-oxoglutarate 5-dioxygenases 1, 2, and 3 are potential prognostic indicators in patients with clear cell renal cell carcinoma. Aging, 2019, 11, 6503-6521.	1.4	13

#	ARTICLE	IF	CITATIONS
55	Surgical treatment of primary disease for penile squamous cell carcinoma: A Surveillance, Epidemiology, and End Results database analysis. Oncology Letters, 2015, 10, 85-92.	0.8	12
56	Functional variants of the 5-methyltetrahydrofolate-homocysteine methyltransferase gene significantly increase susceptibility to prostate cancer: Results from an ethnic Han Chinese population. Scientific Reports, 2016, 6, 36264.	1.6	12
57	Lowâ€serum prostateâ€specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer. Prostate, 2019, 79, 1563-1571.	1.2	12
58	Prognostic implication and functional annotations of Rad50 expression in patients with prostate cancer. Journal of Cellular Biochemistry, 2020, 121, 3124-3134.	1.2	12
59	Prostate cancer and prostatic diseases Best of China, 2018. Prostate Cancer and Prostatic Diseases, 2019, 22, 1-2.	2.0	11
60	<p>High Expression of CD39 is Associated with Poor Prognosis and Immune Infiltrates in Clear Cell Renal Cell Carcinoma</p>. OncoTargets and Therapy, 2020, Volume 13, 10453-10464.	1.0	11
61	Prognostic significance of the degree of extranodal extension in patients with penile carcinoma. Asian Journal of Andrology, 2014, 16, 437.	0.8	11
62	Nephrometry score-guided off-clamp laparoscopic partial nephrectomy: patient selection and short-time functional results. World Journal of Surgical Oncology, 2016, 14, 163.	0.8	10
63	Waist-hip Ratio (WHR), a Better Predictor for Prostate Cancer than Body Mass Index (BMI): Results from a Chinese Hospital-based Biopsy Cohort. Scientific Reports, 2017, 7, 43551.	1.6	10
64	Construction of a robust prognostic model for adult adrenocortical carcinoma: Results from bioinformatics and realâ€world data. Journal of Cellular and Molecular Medicine, 2021, 25, 3898-3911.	1.6	10
65	Conditional survival among patients with adrenal cortical carcinoma determined using a national population-based surveillance, epidemiology, and end results registry. Oncotarget, 2015, 6, 44955-44962.	0.8	10
66	Genitourinary small-cell carcinoma: 11-year treatment experience. Asian Journal of Andrology, 2014, 16, 705.	0.8	10
67	Performance of the Prostate Health Index in predicting prostate biopsy outcomes among men with a negative digital rectal examination and transrectal ultrasonography. Asian Journal of Andrology, 2016, 18, 633.	0.8	10
68	Identification of prognostic biomarkers in papillary renal cell carcinoma and PTTG1 may serve as a biomarker for predicting immunotherapy response. Annals of Medicine, 2022, 54, 211-226.	1.5	10
69	Smoking increased the risk of prostate cancer with grade groupâ€‰â‰¥â€‰4 and intraductal carcinoma in a prospective biopsy cohort. Prostate, 2017, 77, 984-989.	1.2	9
70	National Comprehensive Cancer Network (NCCN) risk classification in predicting biochemical recurrence after radical prostatectomy: a retrospective cohort study in Chinese prostate cancer patients. Asian Journal of Andrology, 2018, 20, 551.	0.8	9
71	Optical biopsy of bladder cancer using confocal laser endomicroscopy. International Urology and Nephrology, 2019, 51, 1473-1479.	0.6	9
72	Development and validation of a robust multigene signature as an aid to predict early relapse in stage I-III clear cell and papillary renal cell cancer. Journal of Cancer, 2020, 11, 997-1007.	1.2	9

#	Article	IF	Citations
73	Influence of age on predictiveness of genetic risk score for prostate cancer in a Chinese hospital-based biopsy cohort. Oncotarget, 2015, 6, 22978-22984.	0.8	9
74	Comparison of two adjuvant hormone therapy regimens in patients with high-risk localized prostate cancer after radical prostatectomy: primary results of study CU1005. Asian Journal of Andrology, 2016, 18, 452.	0.8	9
75	Factors influencing biochemical recurrence in patients who have received salvage radiotherapy after radical prostatectomy: a systematic review and meta-analysis. Asian Journal of Andrology, 2017, 19, 493.	0.8	9
76	External validation and newly development of a nomogram to predict overall survival of abiraterone-treated, castration-resistant patients with metastatic prostate cancer. Asian Journal of Andrology, 2018, 20, 184.	0.8	9
77	Prognosis of rare pathological primary urethral carcinoma. Cancer Management and Research, 2018, Volume 10, 6815-6822.	0.9	8
78	A single nucleotide polymorphism in CYP1B1 leads to differential prostate cancer risk and telomere length. Journal of Cancer, 2018, 9, 269-274.	1.2	8
79	Intravesical Recurrence After Radical Nephroureterectomy of Upper Urinary Tract Urothelial Carcinoma: A Large Population-Based Investigation of Clinicopathologic Characteristics and Survival Outcomes. Frontiers in Surgery, 2021, 8, 590448.	0.6	8
80	Outcomes of perineal urethrostomy for penile cancer: A 20-year international multicenter experience. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 500.e9-500.e13.	0.8	8
81	The Role of Serine Peptidase Inhibitor Kazal Type 13 (SPINK13) as a Clinicopathological and Prognostic Biomarker in Patients with Clear Cell Renal Cell Carcinoma. Medical Science Monitor, 2019, 25, 9458-9470.	0.5	8
82	Oral etoposide and oral prednisone for the treatment of castration resistant prostate cancer. Kaohsiung Journal of Medical Sciences, 2014, 30, 82-85.	0.8	7
83	Preneoplastic and Primary Scrotal Cancer. Urologic Clinics of North America, 2016, 43, 523-530.	0.8	7
84	MTHFR c.677C>T Inhibits Cell Proliferation and Decreases Prostate Cancer Susceptibility in the Han Chinese Population in Shanghai. Scientific Reports, 2016, 6, 36290.	1.6	7
85	Genetic variants in RTEL1 influencing telomere length are associated with prostate cancer risk. Journal of Cancer, 2019, 10, 6170-6174.	1.2	7
86	Development and validation of a nomogram including lymphocyte-to-monocyte ratio for initial prostate biopsy: a double-center retrospective study. Asian Journal of Andrology, 2021, 23, 41.	0.8	7
87	Association of glutathione S-transferase T1 and M1 polymorphisms with prostate cancer susceptibility in populations of Asian descent: a meta-analysis. Oncotarget, 2015, 6, 35843-35850.	0.8	7
88	Prostate volume does not provide additional predictive value to prostate health index for prostate cancer or clinically significant prostate cancer: results from a multicenter study in China. Asian Journal of Andrology, 2020, 22, 539.	0.8	7
89	Alkaline phosphatase velocity in nonmetastatic CRPC. Nature Reviews Urology, 2014, 11, 666-667.	1.9	6
90	The Prognostic Value of Programmed Death-Ligand 1 in a Chinese Cohort With Clear Cell Renal Cell Carcinoma. Frontiers in Oncology, 2019, 9, 879.	1.3	6

#	ARTICLE	IF	CITATIONS
91	Eosinophil percentage elevation as a prognostic factor for overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor. Oncotarget, 2016, 7, 68943-68953.	0.8	6
92	Clinical activity of abiraterone plus prednisone in docetaxel-naïve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer. Asian Journal of Andrology, 2019, 21, 131.	0.8	6
93	Increased expression of tribbles homolog 3 predicts poor prognosis and correlates with tumor immunity in clear cell renal cell carcinoma: a bioinformatics study. Bioengineered, 2022, 13, 14000-14012.	1.4	6
94	Effect of Body mass index on the performance characteristics of PSA-related markers to detect prostate cancer. Scientific Reports, 2016, 6, 19034.	1.6	5
95	Functional variants in the low-density lipoprotein receptor gene are associated with clear cell renal cell carcinoma susceptibility. Carcinogenesis, 2017, 38, 1241-1248.	1.3	5
96	Evaluation of the major changes in eighth edition of the American Joint Committee on Cancer pathological staging for prostate cancer treated with prostatectomy. PLoS ONE, 2017, 12, e0187887.	1.1	5
97	Evaluation of clinical staging of the American Joint Committee on Cancer (eighth edition) for prostate cancer. World Journal of Urology, 2018, 36, 769-774.	1.2	5
98	Preoperative prostate health index predicts poor pathologic outcomes of radical prostatectomy in patients with biopsy-detected low-risk patients prostate cancer: results from a Chinese prospective cohort. Prostate Cancer and Prostatic Diseases, 2018, 21, 64-70.	2.0	5
99	The U Shape of Prostate-specific Antigen and Prostate Cancer-specific Mortality in High-grade Metastatic Prostate Adenocarcinoma. European Urology Focus, 2020, 6, 53-62.	1.6	5
100	Diagnostic Performance of Confocal Laser Endomicroscopy for the Detection of Bladder Cancer: Systematic Review and Meta-Analysis. Urologia Internationalis, 2020, 104, 523-532.	0.6	5
101	Phi-based risk calculators performed better in the prediction of prostate cancer in the Chinese population. Asian Journal of Andrology, 2019, 21, 592.	0.8	5
102	Clinical significance of urine prostatic exosomal protein in the diagnosis of prostate cancer. American Journal of Cancer Research, 2019, 9, 1074-1078.	1.4	5
103	Risk factors of perioperative complications in patients undergoing radical retropubic prostatectomy: A ten-year experience. Journal of Huazhong University of Science and Technology [Medical Sciences], 2017, 37, 379-383.	1.0	4
104	Efficacy and safety of first-line sunitinib in Chinese patients with metastatic renal cell carcinoma. Future Oncology, 2018, 14, 1835-1845.	1.1	4
105	Primary tumor surgery improves survival in non-metastatic primary urethral carcinoma patients: a large population-based investigation. BMC Cancer, 2021, 21, 857.	1.1	4
106	Penile rehabilitation after radical prostatectomy: patients' attitude and feasibility in China. Translational Andrology and Urology, 2013, 2, 4-9.	0.6	4
107	Identification and validation of novel metastasis-related signatures of clear cell renal cell carcinoma using gene expression databases. American Journal of Translational Research (discontinued), 2020, 12, 4108-4126.	0.0	4
108	Development of a preliminary nomogram to predict progression of bone scan for castration-resistant prostate cancer. OncoTargets and Therapy, 2015, 8, 713.	1.0	3

#	Article	IF	Citations
109	Functional interaction of fibroblast growth factor 8b and androgen in prostate cancer cell proliferation. Tumor Biology, 2017, 39, 101042831769596.	0.8	3
110	Triptorelin relieves lower urinary tract symptoms in Chinese advanced prostate cancer patients: a multicenter, non-interventional, prospective study. BMC Urology, 2018, 18, 23.	0.6	3
111	Tumor growth velocity: A modified tumor growth rate defining tumor progression during sorafenib treatment in patients with metastatic renal cell carcinoma. International Journal of Urology, 2019, 26, 75-82.	0.5	3
112	A 5-lncRNA Signature Associated with Smoking Predicts the Overall Survival of Patients with Muscle-Invasive Bladder Cancer. Disease Markers, 2021, 2021, 1-10.	0.6	3
113	Prognostic value of PTEN in de novo diagnosed metastatic prostate cancer. Asian Journal of Andrology, 2022, 24, 50.	0.8	2
114	Clear Cell Papillary Renal Cell Carcinoma Shares Distinct Molecular Characteristics and may be Significantly Associated With Higher Risk of Developing Second Primary Malignancy. Pathology and Oncology Research, 2021, 27, 1609809.	0.9	2
115	Prognostic Value of an Immunohistochemical Signature in Patients With Bladder Cancer Undergoing Radical Cystectomy. Frontiers in Oncology, 2021, 11, 641385.	1.3	1
116	Impact of radiation therapy on perineal urethrostomy for penile cancer. Clinical and Translational Radiation Oncology, 2021, 30, 84-87.	0.9	1
117	C-Reactive Protein Levels and Survival Following Cytoreductive Nephrectomy in 118 Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib: A Retrospective Study. Medical Science Monitor, 2019, 25, 8984-8994.	0.5	1
118	Locoregional surgical treatment improves the prognosis in patients with primary metastatic testicular cancer with a single bone or brain metastasis. Molecular and Clinical Oncology, 2020, 13, 146-154.	0.4	1
119	Prognostic value of primary tumor surgery in seminoma patients with distant metastasis at diagnosis: a population-based study. Asian Journal of Andrology, 2020, 22, 602.	0.8	1
120	Survival in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib With or Without Cryoablation. Frontiers in Oncology, 2021, 11, 762547.	1.3	1
121	Prognosis of the Metachronous and Synchronous Bilateral Renal Cancer and Second Primary Cancer After the Bilateral Renal Cancer: a Population-Based Analysis. SN Comprehensive Clinical Medicine, 2019, 1, 900-904.	0.3	0
122	ASO Author Reflections: T1b Penile Cancer: An Alarm to Improve Treatment. Annals of Surgical Oncology, 2019, 26, 692-693.	0.7	0
123	Early prostate specific antigen decline and its velocity are independent predictive factors for outcomes of mCRPC patients treated with abiraterone acetate. Military Medical Research, 2022, 9, 5.	1.9	0